More recently, Glasheen and colleagues showed that melanoma cells with and without BRAF mutations have elevated levels of the cIAP2 protein (the BIRC3 gene product), which mediates tumor cell resistance to MEK inhibitors [39]. This evidence concerns the gene BIRC3 and neoplasm.